Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Fallbeskrivning. Rosiglitazonbehandling gav kraftfull effekt, men fick ändå avbrytas

A case report. Rosiglitazone treatment was highly effective yet had to be terminated

In English

Författare

Summary, in English

The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.

Avdelning/ar

Publiceringsår

2002

Språk

Svenska

Sidor

407-410

Publikation/Tidskrift/Serie

Läkartidningen

Volym

99

Issue

5

Dokumenttyp

Artikel i tidskrift

Förlag

Swedish Medical Association

Ämne

  • Endocrinology and Diabetes
  • Nutrition and Dietetics

Status

Published

Forskningsgrupp

  • Diabetes - Clinical Obesity
  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Övrigt

  • ISSN: 0023-7205